NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis $114.79 -0.29 (-0.25%) (As of 03:44 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Neurocrine Biosciences Stock (NASDAQ:NBIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$114.45▼$117.5750-Day Range$111.62▼$152.8152-Week Range$103.63▼$157.98Volume438,428 shsAverage Volume846,923 shsMarket Capitalization$11.55 billionP/E Ratio34.68Dividend YieldN/APrice Target$163.91Consensus RatingModerate Buy Company OverviewNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More… Elon Musk Drops Stunning Bombshell? (Ad)Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While delivering the death blow to some of the world’s BIGGEST companies. Why is no one talking about it?Click here now to learn what was discussed in this closed-door event – and how to position yourself. Neurocrine Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks99th Percentile Overall ScoreNBIX MarketRank™: Neurocrine Biosciences scored higher than 99% of companies evaluated by MarketBeat, and ranked 22nd out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 18 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth68.74% Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 68.74% in the coming year, from $4.19 to $7.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 34.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 34.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 134.46.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 5.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.43% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 9.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Sustainability and ESG2.9 / 5Environmental Score-2.61 Percentage of Shares Shorted2.43% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 9.87%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.27 News SentimentNeurocrine Biosciences has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Neurocrine Biosciences this week, compared to 10 articles on an average week.Search Interest5 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows9 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,999,632.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. NBIX Stock News HeadlinesImplied Volatility Surging for Neurocrine Biosciences (NBIX) Stock OptionsOctober 24 at 11:45 AM | msn.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $114.00October 20, 2024 | americanbankingnews.comElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While delivering the death blow to some of the world’s BIGGEST companies. Why is no one talking about it?October 24, 2024 | Paradigm Press (Ad)Neurocrine Biosciences Inc.October 19, 2024 | wsj.comLeerink Partnrs Has Negative Outlook for NBIX Q3 EarningsOctober 19, 2024 | americanbankingnews.comLeerink Partnrs Has Optimistic Outlook of NBIX Q4 EarningsOctober 18, 2024 | americanbankingnews.comBarclays Sticks to Its Buy Rating for Neurocrine (NBIX)October 17, 2024 | markets.businessinsider.comState Street Corp's Strategic Acquisition in Neurocrine Biosciences IncOctober 17, 2024 | finance.yahoo.comSee More Headlines NBIX Stock Analysis - Frequently Asked Questions How have NBIX shares performed this year? Neurocrine Biosciences' stock was trading at $131.76 at the beginning of the year. Since then, NBIX stock has decreased by 12.7% and is now trading at $115.01. View the best growth stocks for 2024 here. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings results on Thursday, August, 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.15 by $0.52. The firm's revenue for the quarter was up 30.4% on a year-over-year basis. Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' top institutional investors include Allspring Global Investments Holdings LLC (0.69%), DekaBank Deutsche Girozentrale (0.12%), Tobam (0.07%) and Raymond James & Associates (0.06%). Insiders that own company stock include Neurocrine Biosciences Inc, Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Eric Benevich, William H Rastetter, Darin Lippoldt, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Eiry Roberts, Malcolm Lloyd-Smith, Julie Cooke, Jude Onyia, David W Boyer, Ingrid Delaet, Shalini Sharp, Leslie V Norwalk and George J Morrow. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Humana (HUM), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings8/01/2024Today10/24/2024Next Earnings (Confirmed)10/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,400Year FoundedN/APrice Target and Rating Average Stock Price Target$163.91 High Stock Price Target$219.00 Low Stock Price Target$114.00 Potential Upside/Downside+41.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)$3.63 Trailing P/E Ratio35.10 Forward P/E Ratio27.73 P/E GrowthN/ANet Income$249.70 million Net Margins16.00% Pretax Margin21.08% Return on Equity14.86% Return on Assets10.54% Debt Debt-to-Equity RatioN/A Current Ratio4.19 Quick Ratio4.08 Sales & Book Value Annual Sales$2.12 billion Price / Sales5.52 Cash Flow$2.68 per share Price / Cash Flow43.28 Book Value$22.72 per share Price / Book5.11Miscellaneous Outstanding Shares100,637,000Free Float96,634,000Market Cap$11.69 billion OptionableOptionable Beta0.36 Social Links This page (NASDAQ:NBIX) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredAre You Holding the Winning Hand in the Copper Market?Are You Holding the Winning Hand in the Copper Market?Market JAR | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAccording to Steven Lubka, head of a private equity firm with over $250M in assets under management, "Bitcoin ...Crypto 101 Media | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.